Methotrexate injection syringe 10mg/ml 2 ml №1

Composition and release form

1 ml solution for injection - 10 mg; Patients in the 1 or 5 ml, in the box 1 bottle.

pharmachologic effect

Pharmacological action - antitumor, cytostatic.

Is an antimetabolite antagonist of folic acid. Inhibits dihydrofolate reductase and inhibits the formation of tetrahydrofolate, which is involved in the biosynthesis of nucleic acids (transfer of single-carbon fragments).

Pharmacodynamics

Suppresses mitosis, the growth of actively proliferating tissues (including bone marrow), inhibits the progression of tumors.

Indications drug Methotrexate-Ebeve

Acute lymphocytic leukemia, lymphogranulomatosis, head and neck cancer (squamous), lung, mammary gland; testicular and ovarian tumors; chorionepithelioma, soft tissue sarcoma, osteosarcoma, Ewing's sarcoma; retinoblastoma; trophoblastic disease (mono- and combination therapy), autoimmune diseases, psoriasis (with refractoriness to other types of treatment).

Contraindications

Hypersensitivity, abnormal liver function and kidney function; bone marrow hypoplasia, leukopenia, thrombocytopenia, anemia; infectious diseases; ulcers in the mouth and gastrointestinal tract, postoperative conditions, pregnancy, breast-feeding.

Use during pregnancy and lactation

Contraindicated.At the time of treatment should stop breastfeeding.

Side effects

Nausea, vomiting, difficulty swallowing, gingivitis, stomatitis, ulceration of the mucous membranes of the gastrointestinal tract, hemorrhages and other disorders of the digestive system and liver function, myelosuppression, immunosuppression, disorders of the genitourinary system (urinary disorders, electrolyte balance, genital function); skin manifestations (erythema, alopecia, acne, etc.); headache, convulsions and other signs of CNS damage, allergic reactions.

Dosage and administration

Inside, before eating, without chewing, drinking water; in / m, in / in (bolus, infusion), in / a, intrathecal (subarachnoid). Doses are selected individually, depending on the disease, general condition and blood picture of the patient. Doses above 100 mg / m² body surfaces are injected only into / in a drip (solution or concentrate is pre-diluted with 5% glucose solution to a level of 10 mg (500-1000 ml) and under the protection of Calcium folinate. Intrathecal - 0.2-0.5 mg / kg (8-12) mg / m² a) every 2-3 days; after the disappearance (or reduction) of symptoms, the interval between injections increases to 1 week, then to 1 month; prophylactic - every 6-8 weeks. In psoriasis, psoriatic arthritis, autoimmune diseases - 10–25 mg orally, weekly (it is also possible to administer intravenously or intramuscularly in the same dose); the initial dose is 2.5-5 mg, then the dose is increased to 7.5-25 mg / week (no more than 30 mg / week).

Precautionary measures

It is necessary to monitor the condition of the oral mucosa, liver and kidney function, peripheral blood.

Storage conditions of the drug Methotrexate-Ebeve

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

The shelf life of the drug Methotrexate-Ebeve

Do not use after the expiration date printed on the package.